Compare ACRS & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | TAYD |
|---|---|---|
| Founded | 2012 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 132.1M |
| IPO Year | 2015 | N/A |
| Metric | ACRS | TAYD |
|---|---|---|
| Price | $3.08 | $59.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 5.9K |
| Earning Date | 11-06-2025 | 01-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.72 |
| Revenue | $15,742,000.00 | ★ $44,593,219.00 |
| Revenue This Year | N/A | $10.81 |
| Revenue Next Year | $6.06 | $8.37 |
| P/E Ratio | ★ N/A | $21.68 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $29.50 |
| 52 Week High | $3.48 | $58.95 |
| Indicator | ACRS | TAYD |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 73.16 |
| Support Level | $3.12 | $55.32 |
| Resistance Level | $3.48 | $52.00 |
| Average True Range (ATR) | 0.21 | 2.37 |
| MACD | -0.01 | 0.93 |
| Stochastic Oscillator | 57.06 | 87.54 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.